<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006205</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAAJOH1052207A1</org_study_id>
    <secondary_id>R01AA013964</secondary_id>
    <nct_id>NCT00006205</nct_id>
  </id_info>
  <brief_title>Alcohol Dependency Study: Combining Medication Treatment for Alcoholism</brief_title>
  <official_title>Combining Medications Treatment for Alcoholism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bankole Johnson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn whether ondansetron and topiramate either alone or in
      combination is safe and effective in the treatment of alcohol dependence. This 13 week
      out-patient clinical trial is randomized, double-blind, and placebo-controlled. There are
      post-study follow up visits 1, 2 and 3 months after the end of the study. Participants will
      receive ondansetron and topiramate either alone or in combination or a placebo coupled with
      psychotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a 13 week clinical trial. During the 13 weeks participants receive placebo,
      ondansetron and topiramate alone or in combination. During the 13 weeks participants come to
      an outpatient clinic to receive the study medication, physical checks, and cognitive
      behavioral therapy. The duration of the weekly visit is 3 hours. There is a 1, 2, and 3 month
      post-study follow up visit. Screening for this study is initially done over the telephone and
      takes 15-20 minutes. If there is nothing found to make someone ineligible to participate,
      they come to the out-patient clinic for a more thorough in-clinic screening.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2005</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-report measures of alcohol-related problems and consumption, Objective measures of alcohol consumption</measure>
    <time_frame>Throughout the study</time_frame>
    <description>Drinks per drinking day, Drinks per day, Percent Days Abstinent, BAC, CDT, GGT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication compliance, alcohol craving, social functioning, quality of life, alcohol withdrawal, attendance at psychosocial services, pre-morbid risk factors</measure>
    <time_frame>Throughout the study</time_frame>
    <description>Pill Count, Q-LES-Q, SFQ, AASE, ADBS, OCDS, CIWA-Ar, CGI, TCI, MAC, AOQ, FHAM</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>Ondansetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ondansetron + cognitive behavioral therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topiramate + cognitive behavioral therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + cognitive behavioral therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ondansetron + Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ondansetron + Topiramate + cognitive behavioral therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron + cognitive behavioral therapy</intervention_name>
    <description>ondansetron (4 mcg/kg b.i.d)</description>
    <arm_group_label>Ondansetron</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topiramate + cognitive behavioral therapy</intervention_name>
    <description>topiramate (up to 300 mg/day)</description>
    <arm_group_label>Topiramate</arm_group_label>
    <other_name>Topamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + cognitive behavioral therapy</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron + topiramate + cognitive behavioral therapy</intervention_name>
    <description>ondansetron (4 mcg/kg b.i.d) + topiramate (up to 300 mg/day)</description>
    <arm_group_label>Ondansetron + Topiramate</arm_group_label>
    <other_name>zofran, topamax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current diagnosis of alcohol dependence and drinking greater than or equal to 14
             alcohol drinks/week for women and greater than or equal to 21 alcohol drinks/week for
             men in the last 30 days.

          -  Provide a written, informed consent.

          -  Good physical health and must weigh within at least 40 kg and no more than 140 kg.

          -  Literate in English and able to read, understand, follow instructions, and complete
             questionnaires accurately.

          -  Willingness to participate in behavioral treatments for alcoholism.

          -  Provide evidence of stable residence in the last month prior to enrollment in the
             study and have no plans to move during the next three months.

        Exclusion Criteria:

        Please contact site for additional information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bankole Johnson, DSc, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mindy Borszich</last_name>
    <phone>1-888-882-2345</phone>
    <email>mcb3x@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva Jenkins-Mendoza</last_name>
    <phone>(434) 243-0562</phone>
    <email>emj9c@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia Center for Addiction Research and Education</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mindy Borszich</last_name>
      <phone>888-882-2345</phone>
      <email>mcb3x@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eva Jenkins-Mendoza</last_name>
      <phone>(434)243-0562</phone>
      <email>emj9c@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bankole Johnson, DSc, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nassima Ait-Daoud Tiouririne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Center for Addiction Research and Education</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mindy Borszich</last_name>
      <phone>888-882-2345</phone>
      <email>mcb3x@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eva Jenkins-Mendoza</last_name>
      <phone>(434)243-0562</phone>
      <email>emj9c@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bankole Johnson, DSc, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nassima Ait-Daoud Tiouririne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.medicine.virginia.edu/clinical/departments/psychiatry/sections/neurobiologicalstudies/uvacare</url>
    <description>(UVA CARE Website)</description>
  </link>
  <reference>
    <citation>Johnson BA. An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence. Expert Opin Pharmacother. 2004 Sep;5(9):1943-55. Review.</citation>
    <PMID>15330732</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>September 11, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2000</study_first_posted>
  <last_update_submitted>March 14, 2013</last_update_submitted>
  <last_update_submitted_qc>March 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Bankole Johnson</investigator_full_name>
    <investigator_title>Chair of Psychiatry and Neurobehavioral Sciences</investigator_title>
  </responsible_party>
  <keyword>alcoholism</keyword>
  <keyword>alcohol addiction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

